Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells

Triple negative breast cancer (TNBC) represents approximately 10–15% of all breast cancers and has a poor outcome as it lacks a receptor target for therapy, and TNBC is frequently associated with a germline mutation of BRCA1. Poly (ADP-ribose) polymerase inhibitor (PARPi) drugs have demonstrated som...

Descripción completa

Detalles Bibliográficos
Autores principales: Moustafa, Dina, Elwahed, Maha R. Abd, Elsaid, Hanaa H., Parvin, Jeffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790533/
https://www.ncbi.nlm.nih.gov/pubmed/33412559
http://dx.doi.org/10.1371/journal.pone.0235025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790533/
https://www.ncbi.nlm.nih.gov/pubmed/33412559
http://dx.doi.org/10.1371/journal.pone.0235025

Ejemplares similares